bionaturis

Bionaturis debates about the potentiality of the Biotech sector in Andalusia

Bionaturis is one of the participating companies in the ‘Sessions of Innovative Public Procurement: a development opportunity and business for the Biotech Sector in Andalusia’, organized by Technological Corporation of Andalusia (CTA, in Spanish) and BioAndalucia Association. Bionaturis CEO and president, Victor Infante, will represent the company in this forum to discuss about ‘The Biotech Sector Abilities in Andalusia’, along with the companies Biomedal and NeuronBio.

The relevance of Biotechnology in Andalusia is remarkable high considering that this autonomous community has been leading the foundation of new biotech companies in Spain for five years, according to Asebio. At the international level, its role is also outstanding because, as Extenda has pointed out, Andalusia is the fifth Spanish community in exporting biotech products with 614 million Euros in 2015. Another sign of its importance is that six Andalusian companies took part in the latest edition of the Bio International Convention, held last June in San Francisco, being Bionaturis among them. (Please, click here for further information about that)

With the main goal of identifying the key issues of this kind of Innovative Public Procurement and analyzing how the autonomous, national and European legal tools could contribute to it, these sessions gathers experts from public institutions, companies and research institutions. These sessions, mainly practical, will be held in Seville on July 5th.

For further information about the conference, please click here

About Bionaturis Group

Bionaturis Group offers cutting-edge biotechnological drugs and services for human and animal health. Considered an international benchmark in vaccines research, the biotechnological Group which envisions a global access to health is listed on the Spanish stock exchange for SMEs (ticker BNT). Bionaturis Group has four companies (Bionaturis, Biobide, ZIP Solutions and BNT Pacific) and two subsidiaries (Biobide […]

July 4th, 2016|Blog english, congress|Comments Off|

Bionaturis Group increases recurring sales 21.7%, keeping a CAGR of 24.1% on net sales between 2012 and 2015

Bionaturis Group has released FY2015 audited results showing a continuous growth in many of its main performance indicators at organic level. Thus, the recurring business coming from the CRO and consumer products divisions has grown 21.7% YOY, meaning a CAGR of 24.1% on net sales for the whole group between 2012-15. Regarding the human and animal health division -which business model requires a more focused analysis on the richness and quality of the pipeline- the Group announced the addition of up to six new programs, five of which are targeted specifically to highly lucrative niche markets within animal health, positioning the group as a partner of choice for cutting-edge developments in this sector.

From the angle of an effective presence in other international markets the Group signed an outstanding agreement with the Administrative Committee of the high technology Industrial development zone of Changshu City (Jiangsu, China), which shall support the start up phase of the subsidiary BNT China Biosciences. Also during 2015 the subsidiary BBD Biophenix USA was created, generating an immediate effect on the increase of contracts with U.S. entities, such as the one signed with the NIH (National Institute of Health), a leading global institution in the health sector.

For further details, click here

April 30th, 2016|Blog english, Hechos Relevantes|Comments Off|

Immunization: great progresses and challenges

The World Health Organization (WHO) is celebrating the Immunization Week with the main goal of promoting vaccination to protect people at all ages from diseases. Since Jenner invented the first vaccine against smallpox at the end of XVIII century, the progresses in the prevention area have saved millions of lives worldwide and they will continue doing it in the future.

According to the WHO, immunization Immunization averts an estimated 2 to 3 million deaths every year from diphtheria, tentanus, whooping cough and measles. Other preventable diseases through vaccination are meningitis, hepatitis B, mumps, poliomyelitis and rubella, among others. Although the immunization coverage is higher and higher in the world, there are still a lot of challenges to achieve. The same institution shows that around 18.7 million of breast-fed babies worldwide in 2014 were not covered by the system of vaccination, because of that it is necessary to double efforts.

Further information about immunization coverage (WHO)

Vaccination is one of the mainstays of the preventive medicine, being the flagship for Medicine at the XXI century. Immunization is a broad field of scientific research for human and animal health. Bionaturis, an international benchmark in the development of biologic vaccines for both sectors, is working in this sphere of knowledge. With the main goal of putting ultimate health technologies and products at a more global reach of customers and users, Bionaturis has developed its alternative platform to produce biological products, FLYLIFE, that offers flexibility, high scale-up speed and less demand of space and investment. Bionaturis has a rich portfolio of biologic products as a vaccine against visceral canine leishmaniosis, another one against nematodes in livestock and other vaccines that prevent several diseases in birds, swines and fish in aquaculture. About human health, the […]

April 26th, 2016|Blog english|Comments Off|

Bionaturis, honoured with the prize by Actualidad Economica Magazine within the ‘Revelation’ category

The readers of Actualidad Economica Magazine had chosen Bionaturis as Revelation Company, for its Business Success Awards in the province of Cadiz. As it has been announced today in its February issue, Bionaturis was born as a Spin-Off at Cadiz University ten years ago and today it is a reference company in the development of state-of-the-art biological medicines. According to its vision to offer a more balanced access to first-in-class drugs in the world, Bionaturis is nowadays developing its international expansion.

Other awarded companies and entrepreneurs in our province are Acerinox, Ingemation Ingeniería and the Asociación de Complementos de Moda y Piel de Ubrique, among others.

The award ceremony will be next February in Cadiz.

January 27th, 2016|Blog english|Comments Off|

Internationalization, a priority for the Biotech sector in Spain

Asebio 2014 Annual Report, recently published, shows that internationalization is an essential aspect for the Spanish Biotech sector, in particular for more than 90% of the companies. In fact, 88% are developing nowadays an international activity, among them, exportation, research agreements and participation in European programmes. For the companies that haven´t still started any international activity, this issue is their priority in the short term.

Nowadays, 43 of the companies belonged to Asebio have already given the relevant step of setting up outside our borders, reaching 47 countries in the five continents. At the top of these new markets for Spanish companies are USA, Portugal and Germany, though Latin America is also in a good position. The participation in meetings and forums of the sector is a key instrument for the internationalization and the discovery of potential customers, according to the same report.

Bionaturis Group is working to offer alternative solutions for human and animal health because of its field is global. In this way, the internationalization is essential in its business model. The company is nowadays developing its expansion plan, with the setting up of BBD BioPhenix subsidiary in Maryland (USA) and the recent sign of the strategic agreement for its corporate expansion in China. Bionaturis is also working in its growth in Latin America with the firm of Carmelo Angulo.

Besides the physical presence in other countries, another of the favourite ways of the Biotech sector in its international activity is the strategic alliance, both scientific and commercial. During 2014, 97 international alliances of Spanish companies were formalized abroad. In this sense, Bionaturis Group signed last June an agreement with the company Biological Mimetics inc (BMI), located in USA, with the main goal of developing […]

August 25th, 2015|Blog english|Comments Off|

Corporacion Tecnologica de Andalucia supports Bionaturis in the development of a project on animal health

The initiative Bovihealth aims the development of peptides to be used as health and growth promoter in cattle.

Besides Bionaturis Group, Bovihealth also has the Sociedad Cooperativa Andaluza Ganadera del Valle de los Pedroches (COVAP) as a partner.

 

Jerez de la Frontera, 24st of July, 2015. Corporacion Tecnologica de Andalucia (CTA) has granted the Company with an incentive worth of €147.027,46 to partially fund the Bovihealth project. The initiative aims the development of peptides to be used as health and growth promoter in cattle. The Company partners up in this project with an end-user of the seek products, the Cooperativa del Valle de los Pedroches (COVAP). The incentive is completely subsidized by the Regional Andalusian Government and the Ministry of Economy and Competitiveness of Spain.

“With this initiative we intend to develop effective feeding treatments to boost the immune system of the cattle herd, improving the productivity index at the same time” explains Victor Infante, CEO of Bionaturis Group. “The approach points to reduce the use of traditional antibiotics as far as possible. To that end, we will test some peptides with proven successful activity in other type of livestock (swine, poultry)”

Two public research groups, the group BIO 155 of Analysis of biological macromolecules of interest in biomedicine, which belongs to the CSIC-Instituto López-Neyra, and the group AGR 137 of Animal Anatomical Pathology, of the University of Córdoba (UCO) also collaborate in the project.

About CTA

Corporacion Tecnologica de Andalucia is a private foundation, launched by the Junta of Andalusia and backed by 152 member companies, in order to promote regional innovation on the basis of transference. CTA is dedicated to financing R&D business projects in collaboration with Universities, and offers added services to innovative companies, universities, technological centers […]

July 24th, 2015|Blog english, Press Releases|Comments Off|

Bionaturis and the US-Biotech company BMI sign an agreement for the jointly development of human and animal vaccines

The goal of this strategic partnership is to join forces to bring to market new and improved biopharmeutical products.

As the first step of this agreement, Bionaturis Group will support the manufacturing development of a first-in-class vaccine to prevent the human common cold.

 

Jerez, June 18th 2015. Bionaturis Group and Biological Mimetics, Inc., -BMI- (based in Maryland, USA) has started a new strategic collaboration agreement to jointly develop new vaccines for human and animal health applications.

In the context of this agreement Bionaturis Group will use its proprietary FLYLIFE platform for the production of experimental batches of vaccines designed using BMI’s Immune Refocusing Technology (IRT). Specifically, as part of the agreement, Bionaturis Group has begun the works corresponding to the manufacturing proof of concept of a candidate of BMI of a first in man vaccine against Human Rhinovirus, the cause of the common cold as well as primary infant viral pneumonia and its known associations with asthma.

According to the National Center of Health, in the United States there are around 62 million cases annually of common cold with human rhinovirus infection being the culprit for about 35% of them. There are over 100 different types of rhinoviruses, which makes developing a vaccine against rhinoviruses difficult. According to experts, the economic consequences of absenteeism from work, school and primary care services caused by the common cold have an impact, only in the United States economy, between 35 and 40 billion US dollars a year.

The lead of BMI is designed to become the first in man cross serotype vaccine on the market to prevent and/or limit clinical complications from infection. The vaccine is to undergo preclinical and process development and evaluation, carrying out safety, immunogenicity and efficacy trials using […]

June 18th, 2015|Blog english, Press Releases|Comments Off|

November Newsletter

If you want to know Bionaturis’ latest news, here you are our November Newsletter

IN THIS ISSUE

Bionaturis takes part in the annual meeting of the European project Targetfish
More capacity, results and higher speed by BBD BioPhenix automated platform
Bionaturis’ track-record in European initiatives

Let’s get to know…

Maria Mengual Mesa, 23 years-old, born in El Puerto de Santa Maria (Cadiz), degree in Biotechnology at Pablo de Olavide University.
 

 

-When you were a child, what did you want to be as an adult?
A painter, writer and inventor (my mother used to say that I was going to be Leonardo Da Vinci in the 21st Century).
-What do you like the most about your job?
Knowing that what I am doing is or will be useful in the future.
-What are your future challenges?
Developing as a competent professional in my area and putting into practice the acquired knowledge and future ones to make Bionaturis a reference on the cutting-edge Biotechnology in Spain and abroad.
-Your favourite dish
Croquettes (above all, my grandmother’s ones).
-A place
The beach in El Puerto on a sunny winter day.
-A film
When I was younger, I preferred ‘Sword in the Stone’ because I loved the final sequence when Merlin became a microbe (for me, then, a very little animal) and won the dragon.
-A historical figure
Leonardo Da Vinci.
-A book
‘The Idhún’s Memoirs’, by Laura Gallego
-A song
‘The rain’, by Maria Villalon. It was launched when I went to live far from home the first time.
-What do you usually do in your free time?
I usually dedicate most of my free time doing activities with my Scout Group, on a camping trip or with my friends.
-You can’t live without….
The sun, but one that in winter is also warming, such as the sun in Cadiz.
-How do you imagine the world […]

November 11th, 2014|Blog english|Comments Off|

Bionaturis’ track-record in European initiatives

Ms Rosa Osuna, Deputy Manager at Bionaturis Group, took part last week in an informative workshop about the main topics of the programme “Food security, sustainable agriculture and forestry, marine and maritime and inland water research and the bioeconomy” within Horyzon 2020 EU R&D funding framework. In particular, PhD Rosa Osuna shared Bionaturis experience in the speech ‘The European projects as part of a funding R&D strategy”. The workshop, organized by Cadiz University and  Agencia Andaluza del Conocimiento, in collaboration with Red Otri Andalusia, was held at Puerto Real University Campus.

The event analysed the funding opportunities for researchers and Andalusian institutions within the programme 2014/2015, and the currently open funding scheme for 2015. The activity was devoted to research groups from private and public institutions.

Bionaturis is taking part in the European Project Targetfish, addressed to develop new vaccines for aquaculture, along with 30 partners from 13 different countries.

Spain, in third position

Exactly, Spain is in third position -behind Germany and The United Kingdom- that has got more funding and projects from Horyzon 2020 EU R&D funding framework. In total, the Spanish candidates has received 224 million euros devoteed to 761 projects.

If you want more information about that, please click here

November 11th, 2014|Blog english, congress|Comments Off|

Uso de cookies

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.

CERRAR